Close 3 Mar 2026 | ~03:18 Engagement Time Many people living with multiple sclerosis are already taking GLP-1 medications or seriously considering them for weight management, diabetes, or metabolic health
Mark the reconstitution date on the vial with a small label so you always know how long it has been stored
However, Lilly's triple-agonist candidate, retatrutide (LY3437943), which targets GLP-1, GIP and glucagon receptors, is further along in development
They're both physician-prescribed
11 In addition, GLP-1 receptor agonists have been shown to influence satiety signaling within the central nervous system, promoting feelings of fullness that can result in less caloric intake and eventual weight loss
Topical and transdermal patches occupy a nuanced regulatory category - DSHEA technically applies to ingested products, though many patch brands use DSHEA-style framing and disclaimers as the closest applicable standard